NCT06592859

Brief Summary

This study is a single center, randomized, double-blind, placebo-controlled clinical trial of drug intervention on aging. The purpose is to explore the effectiveness of NMN on the premise of ensuring the safety of oral drug, in order to provide effective intervention means for delaying aging and improve the quality of life of the elderly population. The main outcome measures of this study were the efficacy and safety of NMN on aging intervention.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P75+ for not_applicable

Timeline
8mo left

Started Aug 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Aug 2023Dec 2026

Study Start

First participant enrolled

August 23, 2023

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

July 30, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 19, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 24, 2026

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

June 29, 2025

Status Verified

September 1, 2024

Enrollment Period

2.8 years

First QC Date

July 30, 2024

Last Update Submit

June 25, 2025

Conditions

AgingNMN

Keywords

AgingNMN

Outcome Measures

Primary Outcomes (2)

  • blood NAD+ levels

    NAD+ concentration in serum

    Baseline, 6 months and 12 months

  • SF-36 questionnaire

    Short Form-36 questionnaire is a general health questionnaire consisting of 36 questions. The quality of life among the study participants using questionnaire by comparing with end of study.

    Baseline, 6 months and 12 months

Secondary Outcomes (5)

  • bone density

    Baseline, 6 months and 12 months

  • FVC

    Baseline, 6 months and 12 months

  • FEV1

    Baseline, 6 months and 12 months

  • grip strength test

    Baseline, 6 months and 12 months

  • flexibility of fingers

    Baseline, 6 months and 12 months

Other Outcomes (3)

  • BMI

    Baseline, 6 months and 12 months

  • blood pressure

    Baseline, 6 months and 12 months

  • Changes in the body composition

    Baseline, 6 months and 12 months

Study Arms (2)

NMN Arm

EXPERIMENTAL

NMN Arm participants took one capsule (containing 350mg NMN) with breakfast daily for one year.

Dietary Supplement: NMN

Placebo Arm

PLACEBO COMPARATOR

Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.

Dietary Supplement: placebo

Interventions

NMNDIETARY_SUPPLEMENT

NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.

NMN Arm
placeboDIETARY_SUPPLEMENT

Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.

Placebo Arm

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Local residents of Quzhou or living in Quzhou for over ten years.
  • age 40-50 and 60-70 years old, no major bad habits.
  • Gender unlimited.
  • in good health and has not undergone major surgery within half a year.
  • Be able to communicate well with researchers and cooperate with the work during the study.
  • Written informed consent can be signed voluntarily.

You may not qualify if:

  • Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse.
  • Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
  • Obesity (bmi more than 30).
  • Pregnant/lactating women.
  • Disease history:
  • A) under 60 years old:
  • any cancer (erythrocytosis, except basal cell or squamous cell skin cancer).
  • coronary artery disease/myocardial infarction/clinically significant congestive heart failure.
  • stroke/transient ischemic attack.
  • deep vein thrombosis/pulmonary embolism.
  • serum creatinine \> 1.5 mg/dl (male).
  • poor control of hypertension (although treated, there is still significant hypertension (systolic blood pressure \> 160 mmHg, or diastolic blood pressure \>100 mmHg)).
  • history of active liver disease or metabolic acidosis.
  • chronic kidney disease/hemodialysis treatment, history of severe kidney damage and/or EGFR ≤ 45ml/min/1.73m2.
  • severe autoimmunity/inflammation, such as rheumatoid arthritis, lupus, Crohn\'s disease, etc.
  • +18 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

People's Hospital of Quzhou

Quzhou, Zhejiang, 324000, China

RECRUITING

Central Study Contacts

Feng Zhang

CONTACT

+86-15657053100felix.f.zhang@outlook.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
researcher

Study Record Dates

First Submitted

July 30, 2024

First Posted

September 19, 2024

Study Start

August 23, 2023

Primary Completion (Estimated)

May 24, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

June 29, 2025

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)